Study 1108: Completed Phase ½ Patient population: Expansion cohort including patients with inoperable or metastatic urothelial carcinoma.

They believe that “these findings speak to an opportunity to better align the goals and values of patients from SGM groups with those of their oncologists through targeted education and culturally appropriate supportive care programs.”

The control group, which comprised 225,272 cancer-free individuals, was drawn from an antibody testing programme for essential workers, including education, healthcare and social care staff.

A chart review of patients with metastatic urothelial cancer has identified a significant association between BMI and immune checkpoint inhibitor response and survival. This independent news story was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

The latest findings from the EV-103 study add support for the first-line use of enfortumab vedotin plus pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer. This independent news story was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Jonathan Rosenberg presents data from a randomized noncomparative cohort of the EV-103 trial of enfortumab vedotin, investigating the agent alone or together with pembrolizumab as a first-line option for cisplatin-ineligible patients with advanced urothelial carcinoma. This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Presenting the results in a poster at the ESMO Congress 2022 in Paris, France, the study authors said that “[t]hese first real-world data […] support the findings of the JAVELIN Bladder 100 trial,” which showed a significant improvement in survival with the addition of maintenance avelumab to best supportive care in this patient population and led to the approval of the PD-L1 inhibitor “in various countries worldwide.”

Discussant Sumanta Pal (City of Hope Comprehensive Cancer Center, Duarte, California, USA) commended the COSMIC-313 investigators for using “a contemporary control arm” and for taking “the bold move of comparing a triplet to a doublet.”

Chromatin conformation loops, especially the POU2F2 loop, may have clinical utility as a biomarker in advanced urothelial cancer, suggest exploratory data from the JAVELIN Bladder 100 trial of maintenance avelumab. This independent news story was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

And longer follow-up, of at least an additional 2 years from the enrolment of the last patient, showed an ORR of 29% and a median duration of response of 30.1 months; the ORR was 47% among patients with a CPS of 10% or more.

Finally, they comment on results indicating that DNA repair alterations can predict response to chemotherapy, as well as the general need for biomarkers to guide patient selection and treatment decisions.

Jonathan Rosenberg takes us through the 2-year follow-up data from the EV-301 study comparing enfortumab vedotin with chemotherapy in previously treated patients with advanced urothelial cancer. This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Forty-three percent of patients receiving cabozantinib required a dose reduction, compared with 10% of those given placebo, but no patient in either group discontinued treatment as a result of toxicity.

Maintenance treatment with avelumab improves the long-term outcomes of advanced urothelial cancer patients regardless of their response to first-line chemotherapy and receipt of second-line therapy, suggest exploratory analyses of the JAVELIN Bladder 100 trial.

The COSMIC-021 trial has shown promising efficacy and manageable toxicity of cabozantinib plus atezolizumab for both treatment-naïve and immune checkpoint inhibitor-treated advanced urothelial carcinoma.

Updated data from the phase 3 EV-301 study show that treatment with enfortumab vedotin remains associated with improved outcomes relative to standard chemotherapy in individuals who have received prior treatment for advanced urothelial carcinoma.

If the patient has very low tumor content in the biopsy, so we will use liquid biopsy.